Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Extends Offer for Clarient Shares

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare has extended its previously announced offer to acquire all of the outstanding stock of Clarient until midnight, New York City time, on Dec. 16, 2010.

GE launched the $580 million acquisition offer for the molecular diagnostics and imaging firm in early November. The offer was scheduled to expire yesterday at midnight, but the offer was extended so investors can consider revised disclosures in a US Securities and Exchange Commission document related to the terms of a settlement with shareholders.

Following the announcement of the acquisition in late October, several shareholder lawsuits were filed against Clarient alleging that members of the firm's board of directors had breached their fiduciary duties. According to Clareint's filing with the SEC last week, the suits also alleged that the merger agreement involved "an unfair price, an inadequate sales process, unreasonable deal protection devices, and that defendants agreed to the merger to benefit themselves personally."

On Friday, Clarient entered into a memorandum of understanding with the shareholders to settle the litigation.

As of 5:00 PM on Dec. 2, approximately 48 percent of Clarient's outstanding common shares had been tendered.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.